Ablynx successfully raises €50 million with Secondary Public Offering - Gilde Healthcare

Menu
Menu
Home

Ablynx successfully raises €50 million with Secondary Public Offering

14 maart 2010

GHENT, Belgium – Ablynx, the biopharmaceutical company focused on the discovery and development of Nanobodies®, announced that it has successfully completed its Secondary Public Offering (the “SPO” or “Offering”) raising €50 million.

The offered shares were priced at €7.5 per share. As a result of the Offering, 6,666,667 new shares, equivalent to €50 million, will be issued by Ablynx. Additionally, 400,000 over-allotment shares, equivalent to €3 million, will be allocated. The over-allotment shares are existing shares and if the over-allotment option is exercised in full, this will result in the sale of the over-allotment shares by the Lending Shareholders.
 
KBC Securities NV and UBS Investment Bank acted as Joint Global Coordinators and Joint Bookrunners, while Piper Jaffray Ltd. acted as Co-Manager to the Offering and while KBC Bank NV and Kempen & Co NV acted as selling agent.
 
For more information, please contact:
 
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Meer nieuws

Gilde Healthcare kondigt succesvolle exit aan van portfoliobedrijf Novicare, een specialistische behandeldienst met medische en paramedische (tele)zorg, aan Gimv

Gilde Healthcare, de gespecialiseerde investeerder in de zorgsector, heeft een overeenkomst bereikt over de verkoop van haar Nederlandse portfoliobedrijf Novicare aan Gimv*. Novicare biedt uitbestede medische en paramedische (tele)zorg. Het bedrijf is gespecialiseerd in ouderenzorg...
28 augustus 2025

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline

DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced completion of patient enrolment...
5 augustus 2025

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock...
31 juli 2025